{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IL-15&page=2", "query": { "intervention": "IL-15", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IL-15&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T22:35:21.829Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03579927", "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "CD19 Positive", "Mantle Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Umbilical Cord Blood-derived Natural Killer Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2019-10-03", "completion_date": "2019-10-03", "has_results": false, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-09-18T22:35:21.829Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03579927" }, { "nct_id": "NCT07444632", "title": "Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoid", "Hodgkin Lymphoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "TGFBR2 KO CAR27/IL-15 NK cells", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2026-05-28", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-09-18T22:35:21.829Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07444632" }, { "nct_id": "NCT06358430", "title": "Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Minimal Residual Disease" ], "interventions": [ { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "TROP2-CAR-NK Cells", "type": "DRUG" }, { "name": "Rimiducid (AP1903)", "type": "DRUG" }, { "name": "Lymphodepleting Chemotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2024-12-02", "completion_date": "2029-01-18", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-18T22:35:21.829Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06358430" }, { "nct_id": "NCT07560865", "title": "First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Astrocytoma", "Glioblastoma", "Progressive Disease" ], "interventions": [ { "name": "FT536", "type": "BIOLOGICAL" }, { "name": "Biopsy/ Intratumoral Injection/ Gross Tumor Resection", "type": "PROCEDURE" }, { "name": "Blood/ Cerebrospinal Fluid/ Tumor Pathology", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 9, "start_date": "2026-04-23", "completion_date": "2029-06-01", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-09-18T22:35:21.829Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07560865" }, { "nct_id": "NCT05676749", "title": "C-TIL051 in Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Non Small Cell Lung Cancer" ], "interventions": [ { "name": "C-TIL051", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AbelZeta Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2024-02-29", "completion_date": "2025-12-30", "has_results": false, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-09-18T22:35:21.829Z", "location_count": 3, "location_summary": "New Orleans, Louisiana • Raleigh, North Carolina • Pittsburgh, Pennsylvania", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05676749" }, { "nct_id": "NCT05110742", "title": "Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematological Malignancy" ], "interventions": [ { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "CAR.5/IL15-transduced CB-NK cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2024-04-22", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-18T22:35:21.829Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05110742" }, { "nct_id": "NCT04424927", "title": "PRV-015 in Gluten-free Diet Non-responsive Celiac Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Celiac Disease" ], "interventions": [ { "name": "PRV-015", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Provention Bio, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 388, "start_date": "2020-08-24", "completion_date": "2024-07-30", "has_results": true, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-09-18T22:35:21.829Z", "location_count": 28, "location_summary": "Los Angeles, California • Ventura, California • Denver, Colorado + 25 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Leesburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04424927" }, { "nct_id": "NCT04340596", "title": "Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "N-803 (IL-15 Superagonist)", "type": "BIOLOGICAL" }, { "name": "VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "10-1074", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 118, "start_date": "2021-05-21", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-18T22:35:21.829Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04340596" }, { "nct_id": "NCT03774654", "title": "CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory B-Cell Small Lymphocytic Lymphoma", "Relapsed Adult ALL", "Relapsed CLL", "Relapsed Non Hodgkin Lymphoma" ], "interventions": [ { "name": "CD19.CAR-aNKT cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "3 Years to 75 Years" }, "enrollment_count": 13, "start_date": "2020-04-14", "completion_date": "2040-05-05", "has_results": true, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-18T22:35:21.829Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03774654" }, { "nct_id": "NCT05700630", "title": "Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection", "ART", "Cd4+ Lymphocyte Deficiency", "Lymphoid Tissue; Infection", "Interleukin" ], "interventions": [ { "name": "FT538", "type": "BIOLOGICAL" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2024-07-15", "completion_date": "2024-08-21", "has_results": false, "last_update_posted_date": "2024-02-26", "last_synced_at": "2026-09-18T22:35:21.829Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05700630" } ] }